4-butyl-1-(2-methylpropyl)-1,2,3-triazole | 1260370-19-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-butyl-1-(2-methylpropyl)-1,2,3-triazole
• 英文别名: 4-Butyl-1-(2-methylpropyl)triazole
• CAS: 1260370-19-1
• 化学式: C₁₀H₁₉N₃
• 分子量: 181.281
• InChiKey: MBMJOKVNYGHCKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  isobutyl azide 、 1-己炔 反应 48.0h， 生成 5-butyl-1-(2-methylpropyl)-1,2,3-triazole 、 4-butyl-1-(2-methylpropyl)-1,2,3-triazole
  参考文献：
  名称：

  The effects of ionic liquids on azide-alkyne cycloaddition reactions

  摘要：

  研究了一系列离子液体对叠氮-炔环化反应过程的区域选择性的影响，结果表明受阻最小的三唑的选择性增加。测定了离子液体对该过程活化参数的影响，发现其介于配位盐和非配位盐之间。在存在小浓度水的情况下，活化参数会发生明显变化，这表明了解体系中水含量的重要性。

  DOI：

  10.1039/c0ob00306a

文献信息

• TRIAZOLE MACROCYCLE SYSTEMS
  申请人：Aileron Therapeutics, Inc.

  公开号：EP3301108A1

  公开（公告）日：2018-04-04

  The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their productions.

  本发明提供了新型拟肽大环及其制备和使用方法，以及氨基酸类似物和大环形成连接体，以及用于其生产的试剂盒。
• Peptides comprising non-natural amino acids and methods of making and using the same
  申请人：Longevity Biotech, Inc.

  公开号：US10543255B2

  公开（公告）日：2020-01-28

  This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an α-amino acid and at least one β-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.

  本发明涉及由天然多肽类似物组成的新型组合物，其中类似物包括一种α-氨基酸和至少一种β-氨基酸。给药组合物可用于治疗或预防由生化或生物途径功能障碍引起的多种疾病状态。本发明的组合物和方法特别适用于鉴定体内受体活性的新型治疗调节剂，与天然翻译的多肽相比，本发明的类似物具有更长的半衰期和相关的生物活性。
• Highly active polypeptides and methods of making and using the same
  申请人：Longevity Biotech, Inc.

  公开号：US10772934B2

  公开（公告）日：2020-09-15

  This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an α-amino acid and at least one β-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.

  本发明涉及由天然多肽类似物组成的新型组合物，其中类似物包括一种α-氨基酸和至少一种β-氨基酸。给药组合物可用于治疗或预防由生化或生物途径功能障碍引起的多种疾病状态。本发明的组合物和方法特别适用于鉴定体内受体活性的新型治疗调节剂，与天然翻译的多肽相比，本发明的类似物具有更长的半衰期和相关的生物活性。
• Anthranilyl-adenosinemonosulfamate analogs and uses thereof
  申请人：Memorial Sloan-Kettering Cancer Center

  公开号：US10874686B2

  公开（公告）日：2020-12-29

  Provided herein are compounds of Formula (I) and pharmaceuticals acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, and prodrugs thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment and/or of an infectious disease (e.g., bacterial infection (e.g., P. aeruginosa infection).

  本文提供了式（I）化合物及其药物可接受盐、溶液剂、水合物、多晶体、共晶体、同系物、立体异构体和原药。还提供了涉及本发明化合物的药物组合物、试剂盒和方法，用于治疗和/或传染性疾病（如细菌感染（如绿脓杆菌感染））。
• Peptidomimetic macrocycles and formulations thereof
  申请人：AILERON THERAPEUTICS, INC.

  公开号：US10905739B2

  公开（公告）日：2021-02-02

  Aqueous pharmaceutical formulations, for parenteral administration, comprising peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof wherein the peptidomimetic macrocycle binds to MDM2 and/or MDMX proteins are disclosed. Also disclosed are methods of treating diseases and disorders using the aqueous pharmaceutical formulations disclosed herein.

  本发明公开了包含拟肽大环或其药学上可接受的盐的用于肠外给药的水性药物制剂，其中的拟肽大环与MDM2和/或MDMX蛋白结合。还公开了使用本文公开的水性药物制剂治疗疾病和失调的方法。